SCHEDULE: Vanguard Group Discloses 5.74% Passive Stake in Avadel Pharmaceuticals

The Vanguard Group has reported a 5.74% beneficial ownership stake in Avadel Pharmaceuticals PLC, held for passive investment purposes.

Summary

• The Vanguard Group beneficially owns an aggregate of 5,564,259 shares of Avadel Pharmaceuticals PLC Common Stock.
• This ownership represents 5.74% of the total class of securities.
• Vanguard holds sole voting power over 0 shares and shared voting power over 107,614 shares.
• Vanguard possesses sole dispositive power over 5,361,014 shares and shared dispositive power over 203,245 shares.
• The filing is a Schedule 13G, indicating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: Neutral, as this is a factual disclosure of ownership and does not contain performance metrics, operational updates, or forward-looking statements from the issuer.

Positives

• The Vanguard Group, a prominent institutional investor, has taken a significant 5.74% stake in Avadel Pharmaceuticals PLC, which may be viewed as a vote of confidence in the company.

Future Outlook

Not applicable, as this Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer.

Industry Context

This filing reflects a standard passive investment by a large asset manager in a pharmaceutical company, consistent with broad market index tracking or diversified portfolio strategies.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a major institutional investor like Vanguard may positively influence market perception and investor confidence in Avadel Pharmaceuticals PLC.

Key Dates

Keywords

Avadel Pharmaceuticals PLC, Vanguard Group, Schedule 13G, beneficial ownership, common stock, institutional investment, passive investment